Bioinformatics Articles

  1. Discovery Dialogues: Winston Haynes, VP, Computational Sciences and Engineering, LabGenius Tx 6/5/2026

    DDO interviewed Winston Haynes, VP, computational sciences and engineering, LabGenius Tx, on their T-cell engagers platform, including its lead candidate LGTX-101, a Nectin-4 CD3 molecule showing strong preclinical efficacy.

  2. Discovery Dialogues: Stef van Grieken, CEO, Cradle Bio 6/5/2026

    DDO caught up with Stef van Grieken, CEO of Cradle Bio, which uses AI to speed protein design, putting tools in scientists’ hands. Gains in lead optimization are clear, but safety CMC and tough targets remain key challenges.

  3. Why Rare Cancers Are Often Left Behind In Drug Discovery 4/23/2026

    Combining advances in AI with continued investment in rare cancer research could help bring new treatment options to patients who currently have very few.

  4. AI: The Inflection Point In Retinal Drug Discovery, Development, And Delivery 4/21/2026

    AI won’t replace clinical or biological insight; instead pairing AI with scientific expertise will sharpen and accelerate retinal therapeutic development.

  5. AI, Digitalization, And In Vivo Programming Redefine Cell And Gene Therapy 4/20/2026

    By merging precision genetic engineering with the scalability of nanomedicine and the predictive power of AI, scientists are reshaping the future of human health.

  6. Next‑Generation Omics: Latest Insights From A Growing Field 4/8/2026

    Experts share their latest discovery and translational research using multi-omics technologies at the NextGen Omics Spatial & Data conference in Boston.

  7. AI Drug Discovery Is Revealing The Preclinical Bottleneck 4/8/2026

    For the generative AI revolution in drug discovery to deliver on its promise, the industry needs more than better molecules, it needs a better pipeline architecture.

  8. NAMs In France And Europe: The Current Landscape 3/20/2026

    The EU is establishing a credible and scalable NAM ecosystem, but challenges still need to be overcome before life sciences professionals and patients can reap the benefits.

  9. New Approach Methods In Practice: Where Are We Today? 2/10/2026

    NAMs have moved beyond a technological promise, but now the current challenge is to operationalize their adoption.

  10. AI For NAM-Ready Drug Development: Turning Promise Into Trust 1/30/2026

    AI is naturally situated for NAMs, and its value will be maximized when it is deployed as part of a rigorously validated, evidence-based strategy.